"Although previous studies have noted a distinct difference in survival between patients with nonmetastasized tumors less than 3 cm [stage IA] and tumors more than 3 cm in size [stage IB], little information is available on whether size remains an important determinant of survival in tumors less than 3 cm," said Jeffrey L. Port, MD, assistant professor of cardiothoracic surgery, Department of Cardiothoracic Surgery, Weill-Cornell Medical Center, New York, NY. "Our study indicates that within stage IA, a tumor size difference of even 1 cm can impact survival, leading us to believe that further substaging of stage IA lung cancer is necessary to ensure patients in this stage are receiving the most effective treatment."
Researchers from Weill Medical College of Cornell University evaluated the relationship between tumor size and 5-year survival in patients with stage IA non-small cell lung cancer. Researchers reviewed the history of 244 patients who underwent surgical resection for lung tumors. Overall mortality/survival rates and mortality/survival rates specific to lung cancer were analyzed and compared to tumor size. The overall 5-year survival rate in patients was 71.1 percent, as compared to the overall 5-year disease-specific survival rate of 74.9 percent. In regards to tumor size, disease-specific survival was 81.4 pe
Contact: Jennifer Stawarz
American College of Chest Physicians